Natera (NASDAQ:NTRA) Insider John Fesko Sells 291 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 291 shares of the company’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $206.16, for a total value of $59,992.56. Following the completion of the transaction, the insider owned 187,220 shares of the company’s stock, valued at $38,597,275.20. The trade was a 0.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Fesko also recently made the following trade(s):

• On Monday, April 27th, John Fesko sold 1,688 shares of Natera stock. The shares were sold at an average price of $204.10, for a total transaction of $344,520.80.
• On Tuesday, March 10th, John Fesko sold 707 shares of Natera stock. The shares were sold at an average price of $204.13, for a total transaction of $144,319.91.

Natera Stock Performance

Shares of Natera stock opened at $206.77 on Wednesday. The firm’s 50-day simple moving average is $201.91 and its 200-day simple moving average is $214.51. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $256.36. The firm has a market cap of $29.42 billion, a P/E ratio of -135.14 and a beta of 1.57.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.81. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. The business had revenue of $665.50 million for the quarter, compared to analyst estimates of $600.68 million. During the same period in the previous year, the business earned ($0.41) EPS. On average, equities analysts forecast that Natera, Inc. will post -1.71 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on NTRA shares. Morgan Stanley decreased their target price on shares of Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 3rd. TD Cowen reissued a “buy” rating on shares of Natera in a report on Wednesday, January 7th. William Blair initiated coverage on shares of Natera in a report on Tuesday, April 14th. They set an “outperform” rating for the company. Citigroup initiated coverage on shares of Natera in a report on Wednesday, January 7th. They set a “buy” rating and a $300.00 price target for the company. Finally, Robert W. Baird lifted their price target on shares of Natera from $239.00 to $257.00 and gave the company an “outperform” rating in a report on Friday, February 27th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $253.47.

More Natera News

Here are the key news stories impacting Natera this week:

• Neutral Sentiment: CEO Steven Leonard Chapman sold 902 shares (≈$185,956) under a pre-arranged Rule 10b5-1 plan to cover taxes on vested awards. This reduced his ownership by ~0.60%. SEC Form 4
• Neutral Sentiment: Insider John Fesko sold 291 shares (≈$59,993) under a Rule 10b5-1 plan to cover tax withholding, a ~0.16% reduction in his stake. SEC Form 4
• Neutral Sentiment: Insider Solomon Moshkevich sold 3,405 shares (≈$693,564) under a pre-arranged plan to cover taxes, reducing his holding by ~2.34%. SEC Form 4
• Neutral Sentiment: CFO Michael Burkes Brophy executed two 10b5-1 sales (482 shares at ~$210.49 and 313 shares at ~$206.16) totaling ~795 shares (~$165,984) to cover tax withholdings, trimming his stake by under 1%. SEC Form 4

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of NTRA. Coatue Management LLC boosted its stake in shares of Natera by 1,446.1% in the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock valued at $603,270,000 after purchasing an additional 2,463,008 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Natera by 94.7% in the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after purchasing an additional 2,420,263 shares during the last quarter. Norges Bank bought a new position in shares of Natera in the 4th quarter valued at about $372,398,000. JPMorgan Chase & Co. boosted its stake in shares of Natera by 10.5% in the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after purchasing an additional 1,225,420 shares during the last quarter. Finally, Franklin Resources Inc. boosted its stake in shares of Natera by 37.5% in the 3rd quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock valued at $428,987,000 after purchasing an additional 727,366 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.